Princeton, N.J., Shanghai, and Suzhou, China - December 4, 2024. Duality Biologics, a clinical-stage biotech company, has announced an exclusive option agreement with GSK for the development of DB-1324, a next-generation antibody-drug conjugate (ADC) targeting gastrointestinal cancer.
The agreement allows GSK to obtain a license for worldwide commercialization of DB-1324, excluding mainland China, Hong Kong, and Macau. GSK will pay $30 million upfront, with potential milestone payments totaling up to $975 million upon successful development and commercialization.
DB-1324 is currently in preclinical development and aims to address a significant medical need, as gastrointestinal cancer accounts for 35% of cancer-related deaths globally. The ADC technology is expected to complement GSK's oncology portfolio with novel combination therapies.
Hesham Abdullah, GSK’s SVP and Global Head of Oncology R&D, emphasized the company’s commitment to advancing ADCs as a promising treatment modality for challenging tumor types. John Zhu, CEO of Duality Biologics, expressed optimism about the collaboration, highlighting the potential to provide innovative treatment options for patients with gastrointestinal cancer.